

Review Article

Potential Effects of Nigella Sativa Supplementation in Coronary Heart Disease and other Cardiovascular Diseases

Dina M. Qahwaji^{1*}, Abdulhalim S. Serafi²

¹Clinical Nutrition Department, Faculty of Applied Medical Sciences, King Abdulaziz University, Jeddah, Saudi Arabia

²Department of Physiology, Faculty of Medicine, Umm Al-Qura University (UQU), Makkah, Saudi Arabia

ARTICLE

INFO

Received: 22/02/2023

Revised: 03/04/2023

Accepted: 09/06/2023

Keywords:

Coronary heart disease (CHD), pathophysiology, Nigella sativa (N. sativa), thymoquinone (TQ), inflammatory markers/ cytokines, creatinine, vitamin D.

*Corresponding author:

Name: Dina M. Qahwaji

E: dqahweji@kau.edu.sa

ABSTRACT

Coronary heart disease (CHD) or coronary artery disease (CAD) is considered one of the world-wide leading causes of death and is characterized by either stenosis or occlusion of coronary arteries leading to myocardial ischemia or infarction respectively. Prevention of risk factors, improvement in biomarker levels and control of CHD are described as a strategic plan for Saudi Vision 2020-2030. Given the beneficial healthy effects of Nigella sativa (N. sativa), and since it is known that the anti-inflammatory and antioxidant effects of N. sativa are interconnected, the objective of this review is to compile and elucidate the potential role of N. sativa and its highly potential component thymoquinone (TQ) in CHD and other cardiovascular diseases. Since studies are rare for understanding the mode of action of N. sativa and TQ, the present review and articles for previous studies were searched through PubMed/Medline, Web of Science, Scopus, and Google Scholar databases using relevant keywords. The available randomized clinical trials (RCTs) that examined the effect of N. sativa supplementation on CHD and other cardiovascular diseases were mainly included. Serum parameters, including mainly the inflammatory markers, lipid profile, serum creatinine, leptin, resistin, ESR, hsCRP, vitamin D and other clinical, pathophysiological and biochemical factors, are discussed in association with the N. sativa supplementation in patients with CHD and other cardiovascular diseases. The present review helps understand the beneficial effects of N. sativa in coronary heart disease and other cardiovascular diseases and explores the underlying mechanisms explaining how N. sativa reverts cardiovascular complications back towards normality.

1. INTRODUCTION

The World Health Organization (WHO) data shows 17.9 million people die due to cardiovascular disease (CVD) each year, and dyslipidaemia is considered the most important atherosclerotic risk factor leading to CVD progression is significantly associated with more than half of the cases with ischemic heart disease world-wide (The World Health Report, 2002; Gupta et al., 2017). Non-HDL-C has been given much importance than determining low-density lipoprotein cholesterol (LDL-C) since non-high-density lipoprotein cholesterol (non-HDL-C) determinations provide a better picture of the association of CHD risk (Liu et al., 2006).

Prevention of risk factors, improvement in biomarker levels and control of CHD have been employed as strategies for Saudi Vision 2020-2030. The present review and innovative descriptions would provide information about the effect of N. sativa in controlling CHD.

Plants as medicine have been used as a therapeutic intervention for a variety of diseases because of their valuable activities as a natural therapy for more than 4000 years (Fong, 2002; Dattner, 2003; Oskouei et al., 2018). N. sativa., black seed or black cumin, is an annual herb and a herbaceous plant used as a traditional remedy in Arab countries, Iran and India, and is about 8-10 inches in height and highly cherished medicinal species belonging to the Ranunculaceae family a dicotyledonous bushy plant with specific characteristics of white or pale to dark blue coloured solitary and self-pollinating flowers, pinnate and segmented leaves and capsule fruits with numerous trigonal seeds (Akram & Afzal, 2016). Seeds of N. sativa give a specific aroma, a bitter and peppery taste (Sturtevant & Hedrick, 1972; Gharby et al., 2015) and are used in herbal medicines. The name of N. sativa was derived from the appearance of its small (1-5 mg in weight) dark grey to black colour seeds (Kokoska et al., 2008). Fruit capsules of N. sativa open and the black seeds are dispersed in the air (Schleicher & Saleh, 1998). The N.

sativa oil and thymoquinone (TQ) in black seed decrease arterial blood pressure and heart rate and have beneficial effects on CAD, stroke and peripheral vascular disorders (Leong et al., 2013). *N. sativa* causes cardiac depression through central mechanisms of the vasomotor centre in the medulla and sympathetic outflow towards the periphery rather than to nitric oxide or eicosanoid (Leong et al., 2013).

Because of the beneficial, healthy effects of *N. sativa*, the present review was compiled to elucidate the potential role of *N. sativa* and its highly potential component TQ in CHD. The relevant published articles were searched through PubMed/Medline, Web of Science, Scopus, and Google Scholar databases using relevant keywords. The available randomized clinical trials (RCTs) that examined the effect of *N. sativa* supplementation on CHD and other cardiovascular diseases were mainly included.

2. CORONARY HEART DISEASE (CHD)

CAD or CHD is one of the worldwide leading causes of death. The World Health Organization (WHO) reports show that 46 % of deaths are due to CHD and 31% of deaths due to cardiovascular diseases across the globe. This situation may worsen in future since various uncontrollable risk factors, mainly diabetes, smoking, obesity, hypercholesterolemia, hypertension etc have been enormously increasing. Hence, future consequences of CAD might be quite alarming (Mack & Gopal, 2016). Changes produced by NSS supplementation in CHD and associated risks have been noticed in several studies (Dehkordi & Kamkhah, 2008; Seif, 2013; Haas et al., 2014; Al Asoom, 2017; Oskouei et al., 2018; Ghoreyshi et al., 2020), that emphasize to review the beneficial effects of *N. sativa*.

It is known that myocardial ischemia can trigger myocardial damage, life-threatening ventricular arrhythmias, and other damaging conditions. The ROS products may cause a decrease in antioxidant activity, lethal ventricular arrhythmias and tissue injury after reperfusion of the ischemic myocardium (Oskouei et al., 2018). ROS has potential significance in the pathophysiology of myocardial infarction (MI) (Rona, 1985; Ojha et al., 2012), and it has been investigated that post-ischemia ROS production and decrease in antioxidant task cause tissue dysfunction and ventricular arrhythmias (Moens et al., 2005). The *N. sativa* is promising for normalizing vascular inflammation and endothelial functions by affecting oxidative markers (Tavakoli-Rouzbehani et al., 2022), coronary angiogenesis (Al Asoom et al., 2017), reduction of C-reactive protein and lipid peroxidation (Kooshki et al., 2020).

It was found that *N. sativa* has antioxidant activity and revealed that postconditioning (PoC) for *N. sativa* can decrease ischemia-reperfusion injury by reducing the formation of ROS and leading to improvement in the myocardial oxidative stress conditions (Ghoreyshi et al., 2020). Kidney function dysfunction occurs with an increased risk for CVD (Hall, 1999). CVD risk is increased partly due to the higher prevalence of older age, diabetes,

hypertension, oxidative stress and dyslipidemia (Culleton et al., 1999). Serum creatinine is also an indicator of insulin, hence, diabetes mellitus is associated with CAD (Rasouli et al., 2005; Harita et al., 2009; Hoseinin & Rasouli, 2009). Serum creatinine was found to be associated with pre-inflammatory markers such as Lp(a), apoAI and hsCRP (Rye et al., 2004; Onat et al., 2013), and independent relation with CAD (Onat et al., 2013). Elevated levels of leptin (Myers et al., 2010; Karbowska & Kochan, 2012) and resistin (Zhang et al., 2003; Reilly et al., 2005) were shown to be associated with increased BMI. This shows that these adipokines might have diagnostic importance in CHD with/ without obesity.

Accumulation of free radicals, membrane lipid peroxidation, and DNA damage mainly related to CHD and other atherosclerotic disorders (Violi et al., 2017; Pignatelli et al., 2018). It is further known that control of cellular detoxification of various exogenous toxins is carried out by Glutathione-S-transferases (GSTs) (Singh, 2015) that perform anti-oxidation activity and protect cells against oxidative stress and related DNA damage (Zhang et al., 2014). Whereas the *N. sativa* extract is considered a potent inducer of apo A-I gene expression, and hence, it has beneficial effects in treating dyslipidemia and CHD (Haas et al., 2014). Furthermore, it has been reported that *N. sativa* detoxifies through glutathione and GSTs, reduces aflatoxin (AF) () B1-DNA adducts, and protects against inhibition of DNA damage (Ates et al., 2021; Farshori et al., 2021). Several of the mentioned changes in CHD and cardiometabolic functions might be normalized via *N. sativa* supplementation (Ahmad et al., 2013; Haas et al., 2014; Shafiq et al., 2014; Asgary et al., 2015; Al Asoom et al., 2017; Kooshki et al., 2020; Razmpoosh et al., 2021; Shoaie-Hagh et al., 2021; Tavakoli-Rouzbehani et al., 2021, 2022; Emamat et al., 2022; Rashidmayvan et al., 2022).

3. NIGELLA SATIVA

Nigella sativa has been considered an herb having healing properties. Hence, it has been in use for centuries as an anti-inflammatory, hypotensive, immune-potentiating and has various other uses as a remedy and benefits for health (Akram & Afzal, 2016). The *N. sativa* is mostly distributed in Southern Europe, North Africa, and Asia Minor. Its originating countries are in the south and east Mediterranean Sea to India, Pakistan and Iran (Gharby et al., 2015). Furthermore, *N. sativa* has an amazing rich religious and historical background (Goreja, 2003).

N. sativa was used as a condiment and spice product (Cheikh-Rouhou et al., 2008; Kiralan et al., 2014; Maulidiani et al., 2015), for preparing dietary supplements and functional cosmetics (Kiralan et al., 2014; Pop et al., 2018) and for various medical disorders (Tariq, 2008; Boçsan et al., 2018; Mousavi et al., 2018; Neag et al., 2018). For obtaining information about the effect of *N. sativa* supplementation on obesity and obesity indices, a systematic review and meta-analysis were conducted to systematically review the available randomized clinical trials (RCTs) to see the effects of *N. sativa* on bodyweight (BW), body mass index (BMI), and waist circumference

(WC) in adults (Mousavi et al., 2018). A significant effect of *N. sativa* supplementation on BW and BMI was found in adults. However, the effect of *N. sativa* supplementation on WC was not found to be significant in this meta-analysis (Mousavi et al., 2018).

It has been documented that *N. sativa* has more than a hundred compounds (Khan et al., 2016; Pop et al., 2018) and is used in a mixture form or bioactive metabolites (Gilani et al., 2001; Ait Mbarek et al., 2007; Ahmad et al., 2013, 2021) shows potential health benefits. The curative and therapeutic features of *N. sativa* and its large number of components/ compounds, presenting *N. sativa* as a cytoprotective medicinal plant used for the prevention and treatment of many complicated diseases, and functional and disease-related effects of *N. sativa* were reviewed in detail (Khan et al., 2016). A comprehensive review of the pharmacological effects and mode of action of various components was described for various clinical conditions and disorders (Pop et al., 2018). The crude extracts of NSS were found to have spasmolytic and bronchodilator properties in their organic components, possibly by blocking the calcium channels (Gilani et al., 2001). While studying to determine *in vitro* and *in vivo* anti-cancer effect of NSS extracts in mouse models, it was revealed that the administration of NSS into the tumour site caused inhibition of the incidence of liver metastasis development and resultantly led to improvement in survival (Ait Mbarek et al., 2007). The NSS has been widely used as an antihypertensive, diuretic, liver tonic, appetite stimulant, anti-diarrheal, antibacterial, analgesic, antidiabetic, immunomodulator, anti-inflammatory, bronchodilator, spasmolytic, hepato-protective, gastro-protective, reno-protective, antioxidant, and having a variety of other effects (Ahmad et al., 2013, 2021). Owing to the significant involvement of oxidative stress and dyslipidemia in CHD, the hypolipidemic effect of *N. sativa* administration was investigated in diet-induced hypercholesterolemia (Fatima et al., 2007). Significantly reduced levels of TC, triglyceride and LDL-C and elevated levels of HDL-C were investigated. Furthermore, beneficial effects were seen for serum levels of glucose, alanine transaminase (ALT), aspartate transaminase (AST) and the antioxidant glutathione (GSH), which suggested the cardioprotective and antiatherogenic effects of dietary *N. sativa* supplementation in experimentally induced hypercholesterolemia (Fatima et al., 2007).

It was noted that most of the beneficial effects of NSS are due to thymoquinone, that is a major bioactive component in NSS (Ahmad et al., 2013; Srinivasan, 2018; Mazaheri et al., 2019; Majdalawieh et al., 2021). The main constituents of *N. sativa* NS have been extensively reported previously (Mamun & Absar, 2018). These are : 30-40 % crude fat (fixed and volatile oil containing a wide range of fatty acids such as linoleic, oleic, linolenic and palmitic acids), 20-30 % crude protein, 5-10 % crude fibre and potassium, sodium, magnesium, phosphorus, calcium and other minerals.

The most important bioactive ingredients in *N. sativa* are thymoquinone, phytosterols, nigellone, vitamins, fatty acids and minerals (Amin et al., 2016; Mamun & Absar,

2018). It has been studied that most of the potential effects in *N. sativa* are due to main seed essential oil constituent thymoquinone (TQ) (an important active constituent in both volatile and fixed oil) (Cheikh-Rouhou et al., 2007; Ahmad et al., 2013; Gholamnezhad et al., 2016; Srinivasan, 2018; Oskouei et al., 2018; Mazaheri et al., 2019; Majdalawieh et al., 2021). *N. sativa* seeds contain monoterpenes, sesquiterpenes and derivatives (Pop et al., 2018), and indazole alkaloids, saponins (Mehta et al., 2009), cycloartenols (Mehta et al., 2009) and flavonoids (Mehta et al., 2009; Maulidiani et al., 2015). The biological activity of *N. sativa* is mainly due to volatile oil compounds, especially TQ (Burits & Bucar, 2000; Padhye et al., 2008). Hydrodistillation, microwave-assisted extraction, super critical fluid extraction, and the Botnick method are used for obtaining the essential oil of *N. sativa* (Liu et al., 2011; Botnick et al., 2012; Kalidasu et al., 2017). Whereas non-volatile compounds in *N. sativa* are isoquinoline alkaloids e.g. nigellicimine and pyrazol alkaloids, nigellidine and nigellicine, saponins, carbohydrates, fatty acids, proteins, fixed oils, phenolic compounds, and calcium, potassium and iron (Al-Gaby, 1998; Forouzanfar et al., 2014; Tavakkoli et al., 2017).

N. sativa has been found effective for the treatment of other conditions/ disorders, including: toothache, flatulence, as a choleric, anti-spasmodic and uricosuric (Pourbakhsh et al., 2014), anti-inflammatory (Al-Ghamdi, 2001; Hajhashemi et al., 2004), anti-oxidant (Mansour et al., 2002; Kanter et al., 2006; Uz et al., 2008), anti-asthmatic, anti-diabetic, anticancer (Le et al., 2004; Ait Mbarek et al., 2007; Boskabady et al., 2010; Periasamy et al., 2016; Mollazadeh et al., 2017), analgesic (Bashir and Qureshi, 2010; Parvardeh et al., 2018), anti-tumor, and anti-tussive activities (Machmudah et al., 2005; Parvardeh et al., 2005; Ait Mbarek et al., 2007; Hosseinzadeh et al., 2008), anticonvulsant (Hosseinzadeh and Parvardeh, 2004), obesity, nasal congestion, back pain, hypertension, amenorrhea (Ziaee et al., 2012), infections, and intestinal worms (El-Dakhkhny, 1965; Schleicher and Saleh, 1998; Al-Rowais, 2002; Goreja, 2003), anti-microbial ((Kokoska et al., 2008; Forouzanfar et al., 2014; Rafati et al., 2014), hypoglycemic (Kaleem et al., 2006; Meddah et al., 2009) and antilipidemic/ anti-hyperlipidemic (Hawsawi et al., 2001; Bamosa et al., 2002; Ali et al., 2003; Kooti et al., 2016), metabolic (Meddah et al., 2009; Razavi et al., 2014; Hadi et al., 2016), dermatological (Boca, 2018), endocrine, immune, respiratory and cardiovascular (Hosseini et al., 2017; Tavakkoli et al., 2017), as a protective agent against ethanol induced toxicity (Hosseini et al., 2017); an anti-aging agent (Shahroudi et al., 2017) and a protective agent against natural or chemical toxins (Tavakkoli et al., 2017).

4. NIGELLA SATIVA AND CARDIOVASCULAR DISEASES

Studies carried out in acute and chronic models reveal that the anti-inflammatory and antioxidant effects of *N. sativa* are interconnected (Halliwell et al., 1988; Stadtman, 2004). Cardiovascular disease is a leading cause of death worldwide (Prabhakaran et al., 2016). It is mainly

related to the factors of increased serum cholesterol levels, hypertension, smoking, increased LDL/ LDL oxidation, high platelet aggregation, etc. (Rahman & Lowe, 2006) and oxidative stress relating to hypertension, atherosclerosis, heart failure, ischemia-reperfusion and cardiac hypertrophy (Cave et al., 2006).

The mechanism of BP lowering effects of *N. sativa* in humans has shown a reduction in both systolic and diastolic BP (Sahebkar et al., 2016). The antihypertensive effect of *N. sativa* in humans and animals is quite convincing (Khatab & Nagi, 2007; Dehkordi & Kamkhah, 2008). *N. sativa* enhances Na⁺, K⁺, and Cl⁻ excretion (Zaoui et al., 2000) and the thymol extracts cause negative inotropic activity on canine and guinea pig-isolate cardiac preparations (Szentandrassy et al., 2004). TQ helps improve endothelial functions by decreasing oxidative stress and improving the expression of eNOS (Ahmad et al., 2013).

The *N. sativa* has been shown to lower serum cholesterol in animal models and has beneficial effects for treating dyslipidemia (Haas et al., 2014). *N. sativa* affects the lipid profile by reducing serum LDL cholesterol, total cholesterol and triglycerides and increases HDL cholesterol (Li et al., 2004; Nadir et al., 2010; Shafiq et al., 2014) and has beneficial effects in hypercholesterolemia (Sabzghabae et al., 2012) with decrease in triglyceride and LDL-cholesterol levels and an increase in HDL-cholesterol (Bhatti et al., 2009). The ameliorative actions of *N. sativa* are on dyslipidemia or hyperlipidemia (Asgary et al., 2015).

It was revealed that *N. sativa* oil causes improvement in vascular nitric oxide (NO) and flow-mediated dilation (FMD) (Emamat et al., 2022). However, further studies are required to confirm the influence of *N. sativa* oil on vascular inflammation (Table 1). Several related reports are given in Table 1. Use of *N. sativa* oil as medication in CVD patients with hypertension but no hepatic, renal or patient-reported adverse effects showed antihypertensive effects and beneficial control of glucose and lipid metabolism (Shoaei-Hagh et al., 2021). Another report did not find any apparent beneficial effects of *N. sativa* oil administration for the duration of eight weeks (1000 mg/day) in patients with non-alcoholic fatty liver disease (NAFLD) (Rashidmayvan et al., 2022). Higher doses for longer duration may clarify the effect *N. sativa*. Beneficial effects of *N. sativa* supplementation in adults with obesity and overweight status lead to the overall improvement in CVD risk factors (Razmpoosh et al., 2021).

Table 1: Selected representative reports on the potential effects of *N. sativa* supplementation in CHD and other cardiovascular diseases/ risk factors.

Cardiovascular diseases (CVD)	Type of study	Investigations
CVD risk factors	Randomized controlled trial	<i>N. sativa</i> (NS) oil improves vascular nitric oxide (NO) and flow-mediated dilation (FMD) (Emamat et al., 2022).

Hypertension with CVD risk factors	Randomized, double-blind, placebo-controlled-trial	Use of <i>N. sativa</i> seeds oil showing antihypertensive effects, and beneficial effects on glucose control and lipid metabolism in hypertensive patients (Shoaei-Hagh et al., 2021).
Cardiometabolic outcomes in patients with non-alcoholic fatty liver	Randomized double-blind, placebo-controlled-trial	No favourable effect of <i>N. sativa</i> oil (NSO) (1000 mg/day for 8 weeks) on cardiometabolic measures in non-alcoholic fatty liver disease (NAFLD) (Rashidmayvan et al., 2022).
CVD risk factors in obese and overweight women	Crossover, double-blind, placebo-controlled randomized trial	Beneficial effects of <i>N.S</i> supplements among adults with obesity to prevent possible cardiovascular diseases. (Razmpoosh et al., 2021)
Cardiovascular disease risk factors in patients with type 2 diabetes mellitus	Double-blind randomized clinical-trial	The NSO supplement has cardiovascular protective effects in patients with diabetes type-2 (T2DM), by improving the lipid profile, glycemia, and by reducing the C-reactive protein level and the lipid peroxidation (Kooshki et al., 2020)
Coronary artery disease	Randomized, double-blind, placebo-controlled clinical-trial	It suggests a potential beneficiary effect of NS on the metabolic parameters in CAD patients including improvements in anthropometric indices, blood pressure, and FBS (Tavakoli-Rouzbehani et al., 2021)
	randomized, double-blind, placebo-control clinical-trial	NSO supplementation demonstrated a potential beneficial effect on endothelial function by reducing ICAM-1, VCAM-1 levels & affecting oxidative markers. (Tavakoli-Rouzbehani et al., 2022)
Coronary heart disease CHD) prevention	Experimental animal-study	It demonstrated an increase in VEGF and a decrease of the VWF in the hearts of <i>Nigella-fed</i>

		and exercise-trained rats. This might indicate the potentiality for induction of coronary angiogenesis via long-term administration of NS and exercise training. (Al Asoom et al., 2017)
Hyperlipidemia/ dyslipidemia and CHD	Comparative animal-study	NS & simvastatin showed comparable effects in treatment of hyperlipidemia. NS showed protective role in terms of hepatic dysfunction and can be used as a cholesterol lowering agent (Muneera et al., 2015)
	Cell line study for Inducing apolipoprotein A-I gene expression	NSS is a potent inducer of apo A-I gene expression, presumably by enhancing PPAR α /RXR α expression. It has beneficial effects in treating dyslipidemia and CHD (Haas et al., 2014)

Beneficial effects of *N. sativa* supplementation was obtained in patients with type-2 diabetes mellitus having cardiovascular disease risks by improving the lipid profile and glycemia and decreasing lipid peroxidation and C-reactive protein (CRP) (Kooshki et al., 2020). The patients with CAD revealed beneficial effects of *N. sativa* on anthropometric indices, fasting blood sugar (FBS), blood pressure (BP) and metabolic parameters (Tavakoli-Rouzbehani et al., 2021). It was found that the *N. sativa* oil supplementation showed beneficial effect on endothelial cells that decreased intercellular adhesion molecule-1 (ICAM-1), vascular cell adhesion protein 1 (VCAM-1) levels and affected oxidative markers and hence influencing the oxidative markers (Tavakoli-Rouzbehani et al., 2022). CHD prevention was achieved by producing coronary angiogenesis with long-term *N. sativa* supplementation (Al Asoom et al., 2017). Treatment of Hyperlipidemia/ dyslipidemia with CAD was obtained using *N. sativa* supplementation (Haas et al., 2014; Muneera et al., 2015) (Table-1).

Table 1 provides the following further information that some of the potential RCTs conducted for the duration of two months with the daily oral dosages of NSS oil having beneficial effects via:

Improving the vascular nitric oxide (NO) activity and brachial flow-mediated dilation (FMD) without significant change in intracellular adhesion molecule-1 (ICAM-1) and vascular cellular adhesion molecule-1 (VCAM-1) levels in patients with CVD risk factors (Emamat et al., 2022).

Significantly reducing SBP, DBP, total cholesterol (TC), and low-density lipoprotein (LDL), malondialdehyde (MDA) and fasting blood sugar (FBS), and significantly increasing high-density lipoprotein (HDL) and glutathione reductase (GR) (Shoaei-Hagh et al., 2021). Increasing serum HDL-C and reducing levels of LDL-C, TC/HDL-C ratio, serum glutamic-oxaloacetic transaminase and systolic blood pressure, though without any considerable effect on diastolic blood pressure measures. (Razmpoosh et al., 2021).

Decreasing the FBS, triglyceride, TC, LDL-C, serum hs-CRP, MDA and increasing HDL-C in the intervention group compared with the placebo group. (Kooshki et al., 2020).

Significantly reducing the weight, body mass index, waist circumference, hip circumference, waist-to-hip ratio, SBP, DBP, and FBS compared to the placebo group (Tavakoli-Rouzbehani et al., 2021).

Decreasing significantly the serum levels of VCAM-1, ICAM-1, and MDA while increasing the total antioxidant capacity (Tavakoli-Rouzbehani et al., 2022).

The experimental studies in rats showed the beneficial effects of *N. sativa* via:

Increasing significantly the levels of VEGF in rats (Al Asoom et al., 2017).

Improving significantly the lipid profile in rats (Muneera et al., 2015).

However, one major randomized, double-blind, placebo-controlled trial in patients with cardiometabolic complications along with non-alcoholic fatty liver disease (NAFLD) administered with NSS oil for eight weeks did not show statistically significant differences in serum levels of adiponectin, leptin and SBP and DBP (Rashidmayvan et al., 2022). Hence, it was suggested that further studies with higher dosages over a longer period to investigate whether this effect is dose- and time-dependent. A meta-analysis revealed that *N. sativa* supplementation in humans may be beneficial as an antioxidant via increasing the levels of superoxide dismutase (SOD) but shows no significant effect on the level of total antioxidant capacity (TAC) and MDA (Ardiana et al., 2020). There are other studies associated with the supplementation of *N. sativa* that did not reveal any significant change in the levels of MDA, TAC and glutathione peroxidase (GPx) (Kaatabi et al., 2015; Namazi et al., 2015; Hadi et al., 2016; Nikkhah-Bodaghi et al., 2019).

5. NIGELLA SATIVA AND CORONARY HEART DISEASE

The *N. sativa* has been shown to lower serum cholesterol in animal models and has beneficial effects in treating CHD via inducing apo A-1 gene expression by increasing the expression of PPAR α /RXR α (Haas et al., 2014). The *N. sativa* seeds are used for natural therapy and prevention for ischemic heart disease with confirmed dyslipidemia as a risk factor (Asgary et al., 2015), leading to lipid-lowering effects of *N. sativa* to be due to the absorption of intestinal cholesterol absorption/drop in the synthesis of hepatic cholesterol and upregulation process for LDL receptors. An increase in vascular endothelial

growth factor (VEGF) and a decrease of the Von Willebrand factor (VWF) in the hearts of Nigella-fed rats indicated the potential induction of coronary angiogenesis by long-term *N. sativa* administration (Al Asoom, 2017). Beneficial effects of *N. sativa* on cardiac functioning have been shown in human and rat studies (Khattab & Nagi, 2007; Dehkordi & Kamkhah, 2008). Long-term treatment with *N. sativa* showed increased peak force of cardiac contraction, myocardial flow rate and rate of tension development that revealed positive cardiac adaptation for long-term *N. sativa* administration (El-Bahai et al., 2009). Structural remodelling of the myocardium for myocardial hypertrophy and increased diameter of cardiomyocytes was also demonstrated (Al-Asoom LI et al., 2014). Hypertrophied hearts were studied for the effect of *N. sativa* using histological and electrophysiological techniques (Al-Asoom LI et al., 2014), and it was shown that orally induced *N. sativa* for three months in rats revealed a protective effect of *N. sativa* against the ischemia-reperfusion insult in the rat hearts (Seif, 2013). The oxidative stress serves as a trigger for the damage of the heart during the process of oxidative reperfusion (I/R) injury, whereas PoC is used to decrease the resulting conditions of ischemia in reperfusion. Considering this known information, the well-known antioxidant activity of *N. sativa* was studied recently to investigate whether PoC for *N. sativa* can decrease ischemia-reperfusion injury via decreasing ROS (reactive oxygen species) formation (Ghoreyshi et al., 2020). The results showed antioxidant properties of *N. sativa* leading to NS-PoC ameliorating the cardiac activity in isolated heart during I/R in rat via improvement in the myocardial oxidative stress conditions (Ghoreyshi et al., 2020).

Studies carried out in the heart and various other organs and body systems confirming *N. sativa* as a potential treatment approach for ischemic disorders emphasize carrying out further studies and understanding the exact mechanism of action of *N. sativa* (Oskouei et al., 2018). The TQ is an important component of *N. sativa* has a potential influence on myocardial IRI since it decreases the infarct size and arrhythmia score, ventricular tachycardia and ventricular fibrillation (Oskouei et al., 2018).

It has been investigated that antioxidants decrease infarct rate, myocardial dysfunction and occurrence of MI (Goyal et al., 2010; Agrawal et al., 2014). The TQ administration (intraperitoneal 10 mg/kg) in anaesthetized rat was found effective in preserving myocardial IRI-induced lethal ventricular arrhythmias (Tappia et al., 2001; Tullio et al., 2013; Goncaand, Kurt, 2015).

Since ROS has potential significance in pathophysiology of MI (Rona, 1985; Ojha et al., 2012), and it has been investigated that post-ischemia ROS production and decrease in antioxidant task cause tissue dysfunction and ventricular arrhythmias (Moens et al., 2005), the TQ like several other herbal antioxidants IRI (Marczin et al., 2003; Ojha et al., 2008; Frank et al., 2012; Zhang et al., 2014) that has beneficial effects in MI has shown protective effect in myocardial IR damage in rat (Gonca E, Kurt, 2015), causes decrease in oxidative stress in MI in

rat model with chronic treatment for maintaining the activity of antioxidant enzymes in isoproterenol-induced MI (El Tahir et al., 1993), reduces heart rate and arterial blood pressure (El Tahir et al., 1993) and shows cardiovascular activity in *in vitro* studies leading to control of arterial force and rate of constriction intercede via blocking voltage-gated calcium channels (Ghayur et al., 2012). However, there are reports documenting no efficacy of *N. sativa* found for normalizing the BP or the required outcomes in patients with CHD (Qidwai et al., 2009; Bin Sayeed et al., 2013; Kaatabi et al., 2015; Namazi et al., 2015; Hadi et al., 2016; Nikkhah-Bodaghi et al., 2019; Ardiana et al., 2020; Hadi et al., 2021; Rashidmayvan et al., 2022; Kavyani et al., 2023).

A randomized, double-blind trial was carried out to study the effect of oral NSS (1000 mg/day) that did not show any significant change in BP, FBS, and serum levels of lipids, alanine aminotransferase, and creatinine because of the small sample size. A larger study with adequate sample size was recommended (Qidwai et al., 2009). A randomized controlled trial did not show any significant change for the supplementation of *N. sativa* (500 mg twice daily) in the biochemical cardiac markers (TC, triglycerides and HDL-C, very low-density lipoprotein (VLDL), and low-density lipoprotein (LDL) cholesterol, creatine kinase-myocardial band (MB) and SBP and DBP during nine-week study duration (Bin Sayeed et al., 2013). After eight weeks of supplementation with *N. sativa* oil, no statistically significant differences were found in SBP and DBP (Rashidmayvan et al., 2022). No significant effect on the level of total antioxidant capacity (TAC) and MDA could be obtained after *N. sativa* supplementation (Ardiana et al., 2020). Supplementation of *N. sativa* did not show any significant change in the levels of MDA, TAC and glutathione peroxidase (GPx) (Kaatabi et al., 2015; Namazi et al., 2015; Hadi et al., 2016; Nikkhah-Bodaghi et al., 2019).

A randomized controlled clinical trial revealed that HDL-C and homeostatic model assessment for insulin resistance (HOMA-IR) did not change significantly after *N. sativa* supplementation (500 mg per day) for eight weeks. Hence, it was suggested to carry out further long-term trials to confirm the therapeutic efficacy/benefits of *N. sativa* (Hadi et al., 2021). Furthermore, a review study conducted to determine the effect of *N. sativa* supplementation on inflammatory and oxidative markers in adults quite associated with the development of coronary heart disease showed no significant decrease in the levels of interleukin 6 (IL-6) (Kavyani et al., 2023).

The above description reveals that most reports indicate the beneficial effects of *N. sativa* supplementation in CHD. However, though some other reports provide evidence of no change in cardiac markers, antioxidant activity, and inflammatory and oxidative markers, quite a few studies directly point out the absence of the beneficial effect of *N. sativa* supplementation. Considering these reports altogether, it is suggested that *N. sativa* supplementation is generally beneficial for patients with CHD, though it is also suggested for carrying out further studies

with long-duration *N. sativa* supplementation of higher dosages.

6. CONCLUSION AND RECOMMENDATION

Cardiovascular diseases are managed by a variety of synthetic therapeutic products. However, inefficacy, side effects and pharmacokinetic situations incline us to use and predict the effects of natural alternative therapies, including the use of *Nigella sativa* or black cumin, a medicinal plant with rich bioactive compounds and other traditional approaches (Pop et al., 2020). It is quite interesting to note that *N. sativa* and its components show effective pharmacological and antioxidant responses for all cardiovascular risk factors (Pop et al., 2020).

The mechanism of action of *N. sativa* has been proposed. It decreases the synthesis of cholesterol by hepatocytes decreases its adsorption from the small intestine (de Jong et al., 2003). It stimulates cholesterol secretion in bile (Bamosa et al., 2002). Whereas the antioxidant components of *N. sativa* can prevent non-enzymatic lipid peroxidation, an important factor involved in atherosclerosis (Kanter et al., 2005). *N. sativa* decreases the foam cell formation in the blood vessel wall accelerates the local inflammatory response resulting to atherosclerotic plaque formation (Shabana et al., 2013). TQ has been found to improve high cholesterol in the blood and prevent the formation of plaques by decreasing oxidative stress and lipid profile (Ragheb et al., 2008).

It is known that oxidative stress and inflammation are responsible for vascular damage common to hypertension, hyperlipidemia, diabetes, CHD and several other diseases. Controlling these pathologies is of fundamental requirement and importance as they can degenerate into CVDs, which are the main cause of death the world over. The present review provides interesting information that encourages the clinical use of *N. sativa* particularly for CHD and other cardiovascular diseases.

Medicinal plants are used as alternative treatment therapies in a variety of chronic disorders because of their lower cost and reduced side effects. Within this study, the potential anti-inflammatory and antioxidant effects of *N. sativa* in relation to different types of chronic conditions are planned to be investigated. Since both inflammation and oxidative stress are highly interconnected pathophysiological processes influencing themselves, the most recent methods in regard to the experimental settings have been employed. Literature indicates that the use of black cumin in its different forms (as seeds, oil, or different extracts) can be used successfully to treat various inflammatory disorders. It was revealed that because of its pharmacological activities like antioxidant, anti-inflammatory and pro-apoptotic, *N. sativa* can be a valuable product against cardiovascular and related diseases.

It is suggested that further studies with the supplementation of high dosages of *N. sativa* for a longer duration

must be carried out. The *N. sativa* effect on coronary angiogenesis needs to be explored further as it might lead to a new promising preventive and therapeutic agent for ischemic heart disease. Previous studies indicate cardiac adaptation to long-term administration of NS. Further studies with long duration will hopefully help understand the beneficial effects of *N. sativa* in coronary heart disease and explore the underlying mechanisms explaining how various complications lead to CHD and how *N. sativa* reverts these changes back towards normality.

ACKNOWLEDGEMENTS

I acknowledge and thank the Deanship of Scientific Research (DSR) at King Abdulaziz University (KAU), Jeddah, Saudi Arabia, for funding this project under grant no. (RG- 1-140-43). The authors, therefore, acknowledge with thanks DSR's technical and financial support.

REFERENCES

- A Zaoui, Y. Cherrah, Lacaille-Dubois, M. A., Abdellatif Settaf, Hamid Amarouch, & Hassar, M. (2000). [Diuretic and hypotensive effects of *Nigella sativa* in the spontaneously hypertensive rat]. *PubMed*, 55(3), 379–382.
- Agrawal, Y. O., Sharma, P. K., Shrivastava, B., Ojha, S., Upadhyaya, H. M., Arya, D. S., & Goyal, S. N. (2014). Hesperidin Produces Cardioprotective Activity via PPAR- γ Pathway in Ischemic Heart Disease Model in Diabetic Rats. *PLoS ONE*, 9(11), e111212. <https://doi.org/10.1371/journal.pone.0111212>
- Ahmad, A., Husain, A., Mujeeb, M., Khan, S. A., Najmi, A. K., Siddique, N. A., Damanhour, Z. A., & Anwar, F. (2013). A review on therapeutic potential of *Nigella sativa*: A miracle herb. *Asian Pacific Journal of Tropical Biomedicine*, 3(5), 337–352. [https://doi.org/10.1016/s2221-1691\(13\)60075-1](https://doi.org/10.1016/s2221-1691(13)60075-1)
- Ahmad, M. F., Ahmad, F. A., Ashraf, S. A., Saad, H. H., Wahab, S., Khan, M. I., Ali, M., Mohan, S., Hakeem, K. R., & Athar, M. T. (2021). An updated knowledge of Black seed (*Nigella sativa* Linn.): Review of phytochemical constituents and pharmacological properties. *Journal of Herbal Medicine*, 25, 100404. <https://doi.org/10.1016/j.hermed.2020.100404>
- Akram Khan, M., & Afzal, M. (2016). Chemical composition of *Nigella sativa* Linn: Part 2 Recent advances. *Inflammopharmacology*, 24, 67–79. <https://doi.org/10.1007/s10787-016-0262-7>
- Al Asoom, L. I. (2017). Coronary angiogenic effect of long-term administration of *Nigella sativa*. *BMC Complementary and Alternative Medicine*, 17(1). <https://doi.org/10.1186/s12906-017-1795-z>
- Al-Asoom, L. I., Al-Shaikh, B. A., Bamosa, A. O., & El-Bahai, M. N. (2014a). Comparison of *Nigella sativa*- and Exercise-Induced Models of Cardiac Hypertrophy: Structural and Electrophysiological Features. *Cardiovascular Toxicology*, 14(3), 208–213. <https://doi.org/10.1007/s12012-014-9244-4>
- Al-Asoom, L. I., Al-Shaikh, B. A., Bamosa, A. O., & El-Bahai, M. N. (2014b). Effect of *Nigella sativa* Supplementation to Exercise Training in a Novel Model of Physiological Cardiac Hypertrophy. *Cardiovascular Toxicology*, 14(3), 243–250. <https://doi.org/10.1007/s12012-014-9248-0>
- Al-Gaby, A. M. A. (1998). Amino acid composition and biological effects of supplementing broad bean and corn proteins with *Nigella sativa*(black cumin) cake protein. *Nahrung / Food*, 42(05), 290–294. [https://doi.org/10.1002/\(sici\)15213803\(199810\)42:05%3C290::aid-food290%3E3.0.co;2-y](https://doi.org/10.1002/(sici)15213803(199810)42:05%3C290::aid-food290%3E3.0.co;2-y)

- Al-Rowais, N. (2002). Herbal medicine in the treatment of diabetes mellitus. *PubMed*, 23(11), 1327–1331.
- Ali, B. H., & Blunden, G. (2003). Pharmacological and toxicological properties of *Nigella sativa*. *Phytotherapy Research*, 17(4), 299–305. <https://doi.org/10.1002/ptr.1309>
- Alireza Tavakkoli, Ahmadi, A., Bibi Marjan Razavi, & Hosseinzadeh, H. (2017). Black Seed (*Nigella Sativa*) and its Constituent Thymoquinone as an Antidote or a Protective Agent Against Natural or Chemical Toxicities. *PubMed*, 16(Suppl), 2–23.
- Altan Onat, Can, G., Evin Ademoğlu, Etem Çelik, Ahmet Karagöz, & Ender Örnek. (2013). Coronary Disease Risk Curve of Serum Creatinine is Linear in Turkish Men, U-Shaped in Women. *Journal of Investigative Medicine*, 61(1), 27–33. <https://doi.org/10.2310/jim.0b013e318276de59>
- Altan Onat, Hüsnüye Yüksel, Can, G., Bayram Koroğlu, Kaya, A., & Servet Altay. (2013). Serum creatinine is associated with coronary disease risk even in the absence of metabolic disorders. *Scandinavian Journal of Clinical & Laboratory Investigation*, 73(7), 569–575. <https://doi.org/10.3109/00365513.2013.821712>
- Amin, B., & Hosseinzadeh, H. (2015). Black Cumin (*Nigella sativa*) and Its Active Constituent, Thymoquinone: An Overview on the Analgesic and Anti-inflammatory Effects. *Planta Medica*, 82(01/02), 8–16. <https://doi.org/10.1055/s-0035-1557838>
- Ansam Aly Seif. (2013). *Nigella sativa* attenuates myocardial ischemic reperfusion injury in rats. *Journal of Physiology and Biochemistry*, 69(4), 937–944. <https://doi.org/10.1007/s13105-013-0272-5>
- Anwarul Hassan Gilani, Aziz, N., Khurram, I. M., Chaudhary, K., & Iqbal, A. (2001). Bronchodilator, spasmolytic and calcium antagonist activities of *Nigella sativa* seeds (Kalonji): a traditional herbal product with multiple medicinal uses. *PubMed*, 51(3), 115–120.
- Ardiana, M., Pikir, B. S., Santoso, A., Hermawan, H. O., & Al-Farabi, M. J. (2020). Effect of *Nigella sativa* Supplementation on Oxidative Stress and Antioxidant Parameters: A Meta-Analysis of Randomized Controlled Trials. *The Scientific World Journal*, 2020, 1–7. <https://doi.org/10.1155/2020/2390706>
- Asgary, S., Sahebkar, A., & Goli-Malekabadi, N. (2015). Ameliorative effects of *Nigella sativa* on dyslipidemia. *Journal of Endocrinological Investigation*, 38(10), 1039–1046. <https://doi.org/10.1007/s40618-015-0337-0>
- Ates, M. B., & Ortatli, M. (2021). The effects of *Nigella sativa* seeds and thymoquinone on aflatoxin phase-2 detoxification through glutathione and glutathione-S-transferase alpha-3, and the relationship between aflatoxin B1-DNA adducts in broilers. *Toxicol*, 193, 86–92. <https://doi.org/10.1016/j.toxicol.2021.01.020>
- Bamosa, A. O., Ali, B. A., & Al-Hawsawi, Z. A. (2002). The effect of thymoquinone on blood lipids in rats. *PubMed*, 46(2), 195–201.
- Bashir, M., & Hamid Javaid Qureshi. (2010). Analgesic effect of *Nigella sativa* seeds extract on experimentally induced pain in albino mice. *PubMed*, 20(7), 464–467.
- Bhatti, I., Faiz Ur Rehman, Mohammad Asim Khan, & Sarfaraz Khan Marwat. (2009). Effect of prophetic medicine Kalonji (*Nigella sativa* L.) on lipid profile of human beings: an in vivo approach. *World Applied Sciences Journal*, 6(8), 1053–1057.
- Bin Sayeed, M. S., Asaduzzaman, M., Morshed, H., Hossain, M. M., Kadir, M. F., & Rahman, M. R. (2013). The effect of *Nigella sativa* Linn. seed on memory, attention and cognition in healthy human volunteers. *Journal of Ethnopharmacology*, 148(3), 780–786. <https://doi.org/10.1016/j.jep.2013.05.004>
- Boskabadly, M. H., Mohsenpoor, N., & Takaloo, L. (2010). Antiasthmatic effect of *Nigella sativa* in airways of asthmatic patients. *Phytomedicine*, 17(10), 707–713. <https://doi.org/10.1016/j.phymed.2010.01.002>
- Botnick, I., Xue, W., Bar, E., Ibdah, M., Schwartz, A., Joel, D. M., Lev, E., Fait, A., & Lewinsohn, E. (2012). Distribution of Primary and Specialized Metabolites in *Nigella sativa* Seeds, a Spice with Vast Traditional and Historical Uses. *Molecules*, 17(9), 10159–10177. <https://doi.org/10.3390/molecules170910159>
- Cave, A. C., Brewer, A. C., Narayanapanicker, A., Ray, R., Grieve, D. J., Walker, S., & Shah, A. M. (2006). NADPH Oxidases in Cardiovascular Health and Disease. *Antioxidants & Redox Signaling*, 8(5-6), 691–728. <https://doi.org/10.1089/ars.2006.8.691>
- Cheikh-Rouhou, S., Besbes, S., Hentati, B., Blecker, C., Deroanne, C., & Attia, H. (2007). *Nigella sativa* L.: Chemical composition and physicochemical characteristics of lipid fraction. *Food Chemistry*, 101(2), 673–681. <https://doi.org/10.1016/j.foodchem.2006.02.022>
- Cheikh-Rouhou, S., Besbes, S., Lognay, G., Blecker, C., Deroanne, C., & Attia, H. (2008). Sterol composition of black cumin (*Nigella sativa* L.) and Aleppo pine (*Pinus halepensis* Mill.) seed oils. *Journal of Food Composition and Analysis*, 21(2), 162–168. <https://doi.org/10.1016/j.jfca.2007.09.001>
- Chemical investigation of *Nigella sativa* L. seed oil produced in Morocco. (2015). *Journal of the Saudi Society of Agricultural Sciences*, 14(2), 172–177. <https://doi.org/10.1016/j.jssas.2013.12.001>
- Culleton, B. F., Larson, M. G., Wilson, P. W. F., Evans, J. C., Parfrey, P. S., & Levy, D. (1999). Cardiovascular disease and mortality in a community-based cohort with mild renal insufficiency. *Kidney International*, 56(6), 2214–2219. <https://doi.org/10.1046/j.1523-1755.1999.00773.x>
- Dattner, A. M. (2003). From medical herbalism to phytotherapy in dermatology: back to the future. *Dermatologic Therapy*, 16(2), 106–113. <https://doi.org/10.1046/j.1529-8019.2003.01618.x>
- De Jong, A., Plat, J., & Mensink, R. P. (2003). Metabolic effects of plant sterols and stanols (Review). *The Journal of Nutritional Biochemistry*, 14(7), 362–369. [https://doi.org/10.1016/s0955-2863\(03\)00002-0](https://doi.org/10.1016/s0955-2863(03)00002-0)
- Dehkordi, F. R., & Kamkhah, A. F. (2008). Antihypertensive effect of *Nigella sativa* seed extract in patients with mild hypertension. *Fundamental & Clinical Pharmacology*, 22(4), 447–452. <https://doi.org/10.1111/j.1472-8206.2008.00607.x>
- El Tahir, K. E. H., Ashour, M. M. S., & Al-Harbi, M. M. (1993). The cardiovascular actions of the volatile oil of the black seed (*Nigella sativa*) in rats: elucidation of the mechanism of action. *General Pharmacology: The Vascular System*, 24(5), 1123–1131. [https://doi.org/10.1016/0306-3623\(93\)90359-6](https://doi.org/10.1016/0306-3623(93)90359-6)
- El-Bahai, M. N., Al-Hariri, M. T., Yar, T., & Bamosa, A. O. (2009). Cardiac inotropic and hypertrophic effects of *Nigella sativa* supplementation in rats. *International Journal of Cardiology*, 131(3), e115–e117. <https://doi.org/10.1016/j.ijcard.2007.07.075>
- Emamat, H., Mousavi, S. H., Kargar Shouraki, J., Hazrati, E., Mirghazanfari, S. M., Samizadeh, E., Hosseini, M., Hadi, V., & Hadi, S. (2022). The effect of *Nigella sativa* oil on vascular dysfunction assessed by flow-mediated dilation and vascular-related biomarkers in subject with cardiovascular disease risk factors: A randomized controlled trial. *Phytotherapy Research: PTR*, 36(5), 2236–2245. <https://doi.org/10.1002/ptr.7441>
- Ersöz Gonca, & Kurt, Ç. (2015). Cardioprotective effect of Thymoquinone: A constituent of *Nigella sativa* L., against myocardial ischemia/reperfusion injury and ventricular arrhythmias in anesthetized rats. *PubMed*, 28(4), 1267–1273.

- Fatemeh Forouzanfar, Sedigheh, B., & Hosseinzadeh, H. (2014). Black cumin (*Nigella sativa*) and its constituent (thymoquinone): a review on antimicrobial effects. *Pub-Med*, 17(12), 929–938.
- Fong, H. H. S. (2002). Integration of Herbal Medicine Into Modern Medical Practices: Issues and Prospects. *Integrative Cancer Therapies*, 1(3), 287–293. <https://doi.org/10.1177/153473540200100313>
- Frank, A., Bonney, M., Bonney, S., Weitzel, L., Koeppen, M., & Eckle, T. (2012). Myocardial Ischemia Reperfusion Injury. *Seminars in Cardiothoracic and Vascular Anesthesia*, 16(3), 123–132. <https://doi.org/10.1177/1089253211436350>
- Ghayur, M. N., Gilani, A. H., & Janssen, L. J. (2012). Intestinal, Airway, and Cardiovascular Relaxant Activities of Thymoquinone. *Evidence-Based Complementary and Alternative Medicine*, 2012, 1–13. <https://doi.org/10.1155/2012/305319>
- Gholamezhad, Z., Havakhah, S., & Boskabady, M. H. (2016). Preclinical and clinical effects of *Nigella sativa* and its constituent, thymoquinone: A review. *Journal of Ethnopharmacology*, 190, 372–386. <https://doi.org/10.1016/j.jep.2016.06.061>
- Ghoreyshi, M., Mahmoudabady, M., Bafadam, S., & Niazmand, S. (2019). The Protective Effects of Pharmacologic Postconditioning of Hydroalcoholic Extract of *Nigella sativa* on Functional Activities and Oxidative Stress Injury During Ischemia–Reperfusion in Isolated Rat Heart. *Cardiovascular Toxicology*, 20(2), 130–138. <https://doi.org/10.1007/s12012-019-09540-x>
- Gupta, R., Rao, R. S., Misra, A., & Sharma, S. K. (2017). Recent trends in epidemiology of dyslipidemias in India. *Indian Heart Journal*, 69(3), 382–392. <https://doi.org/10.1016/j.ihj.2017.02.020>
- Haas, M. J., Onstead-Haas, L., Emad Naem, Norman C.W. Wong, & Mooradian, A. D. (2014). Induction of apolipoprotein A-I gene expression by black seed (*Nigella sativa*) extracts. *Pharmaceutical Biology*, 52(9), 1119–1127. <https://doi.org/10.3109/13880209.2013.879187>
- Hadi, S., Daryabeygi-Khotbehsara, R., Mirmiran, P., McVicar, J., Hadi, V., Soleimani, D., & Askari, G. (2021). Effect of *Nigella sativa* oil extract on cardiometabolic risk factors in type 2 diabetes: A randomized, double-blind, placebo-controlled clinical trial. *Phytotherapy Research*, 35(7), 3747–3755. <https://doi.org/10.1002/ptr.6990>
- Hadi, V., Sorayya Kheirouri, Alizadeh, M., Alireza Khabbazi, & Hosseini, H. (2016). Effects of *Nigella sativa* oil extract on inflammatory cytokine response and oxidative stress status in patients with rheumatoid arthritis: a randomized, double-blind, placebo-controlled clinical trial. *DOAJ (DOAJ: Directory of Open Access Journals)*, 6(1), 34–43.
- Hajhashemi, V., Ghannadi, A., & Jafarabadi, H. (2004). Black cumin seed essential oil, as a potent analgesic and anti-inflammatory drug. *Phytotherapy Research*, 18(3), 195–199. <https://doi.org/10.1002/ptr.1390>
- HALL, W. D. (1999). Abnormalities of Kidney Function as a Cause and a Consequence of Cardiovascular Disease. *The American Journal of the Medical Sciences*, 317(3), 176–182. <https://doi.org/10.1097/0000441-199903000-00007>
- Halliwell, B., Hoult, J. R., & Blake, D. R. (1988). Oxidants, inflammation, and anti-inflammatory drugs. *The FASEB Journal*, 2(13), 2867–2873. <https://doi.org/10.1096/fasebj.2.13.2844616>
- Hamed Pourbakhsh, Elahe Taghiabadi, Khalil Abnous, Alireza Timcheh Hariri, Sayed Masoud Hosseini, & Hosseinzadeh, H. (2014). Effect of *Nigella sativa* fixed oil on ethanol toxicity in rats. *PubMed*, 17(12), 1020–1031.
- Harita, N., Hayashi, T., Sato, K. K., Nakamura, Y., Yoneda, T., Endo, G., & Kambe, H. (2009). Lower Serum Creatinine Is a New Risk Factor of Type 2 Diabetes: The Kansai Healthcare Study. *Diabetes Care*, 32(3), 424–426. <https://doi.org/10.2337/dc08-1265>
- Hawsawi, Z. A., Ali, B. A., & Bamosa, A. O. (2001). Effect of *Nigella Sativa* (Black Seed) and Thymoquinone on Blood Glucose in Albino Rats. *Annals of Saudi Medicine*, 21(3-4), 242–244. <https://doi.org/10.5144/0256-4947.2001.242>
- Hosseini, S. M., Taghiabadi, E., Abnous, K., Hariri, A. T., Pourbakhsh, H., & Hosseinzadeh, H. (2017). Protective effect of thymoquinone, the active constituent of *Nigella sativa* fixed oil, against ethanol toxicity in rats. *Iranian Journal of Basic Medical Sciences*, 20(8), 927–939. <https://doi.org/10.22038/IJBMS.2017.9116>
- Hosseinzadeh, H., Mollazadeh, H., & Afshari, A. R. (2017). Review on the Potential Therapeutic Roles of *Nigella sativa* in the Treatment of Patients with Cancer: Involvement of Apoptosis. *Journal of Pharmacopuncture*, 20(3), 158–172. <https://doi.org/10.3831/kpi.2017.20.019>
- Hosseinzadeh, H., & Parvardeh, S. (2004). Anticonvulsant effects of thymoquinone, the major constituent of *Nigella sativa* seeds, in mice. *Phytomedicine*, 11(1), 56–64. <https://doi.org/10.1078/0944-7113-00376>
- Hosseinzadeh, H., Shahroudi, M. J., & Mehri, S. (2017). Anti-Aging Effect of *Nigella Sativa* Fixed Oil on D-Galactose-Induced Aging in Mice. *Journal of Pharmacopuncture*, 20(1), 29–35. <https://doi.org/10.3831/kpi.2017.20.006>
- Hosseinzadeh, H., Tavakkoli, A., Mahdian, V., & Razavi, B. M. (2017). Review on Clinical Trials of Black Seed (*Nigella sativa*) and Its Active Constituent, Thymoquinone. *Journal of Pharmacopuncture*, 20(3), 179–193. <https://doi.org/10.3831/kpi.2017.20.021>
- Kaatabi, H., Bamosa, A. O., Badar, A., Al-Elq, A., Abou-Hozafa, B., Lebda, F., Al-Khadra, A., & Al-Almaie, S. (2015). *Nigella sativa* improves glycemc control and ameliorates oxidative stress in patients with type 2 diabetes mellitus: placebo controlled participant blinded clinical trial. *PLoS One*, 10(2), e0113486. <https://doi.org/10.1371/journal.pone.0113486>
- Kaleem, M., Kirmani, D., Asif, M., Qamar Uddin Ahmed, & Bano, B. (2006). Biochemical effects of *Nigella sativa* L seeds in diabetic rats. *PubMed*, 44(9), 745–748.
- Kanter, M. (2005). Hepatoprotective effects of *Nigella sativa* L and *Urtica dioica* L on lipid peroxidation, antioxidant enzyme systems and liver enzymes in carbon tetrachloride-treated rats. *World Journal of Gastroenterology*, 11(42), 6684. <https://doi.org/10.3748/wjg.v11.i42.6684>
- Karbowska, J., & Kochan, Z. (2012). Leptin as a mediator between obesity and cardiac dysfunction. *Postępy Higieny I Medycyny Doświadczalnej*, 66, 267–274. <https://doi.org/10.5604/17322693.997817>
- Kavyani, Z., Musazadeh, V., Golpour-hamedani, S., Moridpour, A. H., Vajdi, M., & Askari, G. (2023). The effect of *Nigella sativa* (black seed) on biomarkers of inflammation and oxidative stress: an updated systematic review and meta-analysis of randomized controlled trials. *Inflammopharmacology*. <https://doi.org/10.1007/s10787-023-01213-0>
- Khattab, M. M., & Nagi, M. N. (2007). Thymoquinone supplementation attenuates hypertension and renal damage in nitric oxide deficient hypertensive rats. *Phytotherapy Research*, 21(5), 410–414. <https://doi.org/10.1002/ptr.2083>
- Kiralan, M., Özkan, G., Bayrak, A., & Ramadan, M. F. (2014). Physicochemical properties and stability of black cumin (*Nigella sativa*) seed oil as affected by different extraction methods. *Industrial Crops and Products*, 57, 52–58. <https://doi.org/10.1016/j.indcrop.2014.03.026>
- Kirn-e Muneera, Majeed, A., & Abdul Khaliq Naveed. (2015). Comparative evaluation of *Nigella sativa* (Kalonji) and simvastatin for the treatment of hyperlipidemia and in the induction of hepatotoxicity. *PubMed*, 28(2), 493–498.

- Kokoska, L., Havlik, J., Valterova, I., Sovova, H., Sajfrtova, M., & Jankovska, I. (2008). Comparison of Chemical Composition and Antibacterial Activity of *Nigella sativa* Seed Essential Oils Obtained by Different Extraction Methods. *Journal of Food Protection*, 71(12), 2475–2480. <https://doi.org/10.4315/0362-028x-71.12.2475>
- Kooshki, A., Tofighiyan, T., Rastgoo, N., Rakhshani, M. H., & Miri, M. (2020). Effect of *Nigella sativa* oil supplement on risk factors for cardiovascular diseases in patients with type 2 diabetes mellitus. *Phytotherapy Research*, 34(10), 2706–2711. <https://doi.org/10.1002/ptr.6707>
- Kooti, W., Hasanzadeh-Noohi, Z., Sharafi-Ahvazi, N., Asadi-Samani, M., & Ashtary-Larky, D. (2016). Phytochemistry, pharmacology, and therapeutic uses of black seed (*Nigella sativa*). *Chinese Journal of Natural Medicines*, 14(10), 732–745. [https://doi.org/10.1016/S1875-5364\(16\)30088-7](https://doi.org/10.1016/S1875-5364(16)30088-7)
- L. Ait Mbarek, Hassan Ait Mouse, Nouredine Elabbadi, Mohamed Khalil Bensalah, A. Gamouh, Rachida Aboufatima, Benharref, A., Chait, A., Kamal, M., Dalal, A., & Abdelmajid Zyad. (2007). Anti-tumor properties of blackseed (*Nigella sativa* L.) extracts. *Brazilian Journal of Medical and Biological Research*, 40(6), 839–847. <https://doi.org/10.1590/s0100-879x2006005000108>
- Le, P. M., Benhaddou-Andaloussi, A., Elimadi, A., Settaf, A., Cherrah, Y., & Haddad, P. S. (2004). The petroleum ether extract of *Nigella sativa* exerts lipid-lowering and insulin-sensitizing actions in the rat. *Journal of Ethnopharmacology*, 94(2-3), 251–259. <https://doi.org/10.1016/j.jep.2004.04.030>
- Leong, X.-F., Rais Mustafa, M., & Jaarin, K. (2013). *Nigella sativa* and Its Protective Role in Oxidative Stress and Hypertension. Evidence-Based Complementary and Alternative Medicine, 2013, 1–9. <https://doi.org/10.1155/2013/120732>
- Liu, J., Sempos, C. T., Donahue, R. P., Dorn, J., Trevisan, M., & Grundy, S. M. (2006). Non-High-Density Lipoprotein and Very-Low-Density Lipoprotein Cholesterol and Their Risk Predictive Values in Coronary Heart Disease. *The American Journal of Cardiology*, 98(10), 1363–1368. <https://doi.org/10.1016/j.amjcard.2006.06.032>
- Liu, X., M. Abd El-Aty, A., & Shim, J.-H. (2011). Various Extraction and Analytical Techniques for Isolation and Identification of Secondary Metabolites from *Nigella sativa* Seeds. *Mini-Reviews in Medicinal Chemistry*, 11(11), 947–955. <https://doi.org/10.2174/138955711797068472>
- M. El-Dakhakhny. (1965). Studies on the Egyptian *Nigella sativa* L. IV. Some pharmacological properties of the seeds' active principle in comparison to its dihydro compound and its polymer. *PubMed*, 15(10), 1227–1229.
- Mack, M., & Gopal, A. (2016). Epidemiology, Traditional and Novel Risk Factors in Coronary Artery Disease. *Heart Failure Clinics*, 12(1), 1–10. <https://doi.org/10.1016/j.hfc.2015.08.002>
- Majdalawieh, A. F., Yousef, S. M., & Abu-Yousef, I. A. (2021). Thymoquinone, a major constituent in *Nigella sativa* seeds, is a potential preventative and treatment option for atherosclerosis. *European Journal of Pharmacology*, 909, 174420. <https://doi.org/10.1016/j.ejphar.2021.174420>
- Mansour, M. A., Nagi, M. N., El-Khatib, A. S., & Al-Bekairi, A. M. (2002). Effects of thymoquinone on antioxidant enzyme activities, lipid peroxidation and DT-diaphorase in different tissues of mice: a possible mechanism of action. *Cell Biochemistry and Function*, 20(2), 143–151. <https://doi.org/10.1002/cbf.968>
- Marczin, N., El-Habashi, N., Hoare, G. S., Bundy, R. E., & Yacoub, M. (2003). Antioxidants in myocardial ischemia-reperfusion injury: therapeutic potential and basic mechanisms. *Archives of Biochemistry and Biophysics*, 420(2), 222–236. <https://doi.org/10.1016/j.abb.2003.08.037>
- Maulidiani, M., Sheikh, B. Y., Mediani, A., Wei, L. S., Ismail, I. S., Abas, F., & Lajis, N. H. (2015). Differentiation of *Nigella sativa* seeds from four different origins and their bioactivity correlations based on NMR-metabolomics approach. *Phytochemistry Letters*, 13, 308–318. <https://doi.org/10.1016/j.phytol.2015.07.012>
- Mazaheri, Y., Torbati, M., Azadmard-Damirchi, S., & Savage, G. P. (2019). A comprehensive review of the physicochemical, quality and nutritional properties of *Nigella sativa* oil. *Food Reviews International*, 35(4), 342–362. <https://doi.org/10.1080/87559129.2018.1563793>
- Meddah, B., Ducroc, R., El Abbes Faouzi, M., Eto, B., Mahraoui, L., Benhaddou-Andaloussi, A., Martineau, L. C., Cherrah, Y., & Haddad, P. S. (2009). *Nigella sativa* inhibits intestinal glucose absorption and improves glucose tolerance in rats. *Journal of Ethnopharmacology*, 121(3), 419–424. <https://doi.org/10.1016/j.jep.2008.10.040>
- Mehta, B. K., Mehta, P., & Gupta, M. (2009). A new naturally acetylated triterpene saponin from *Nigella sativa*. *Carbohydrate Research*, 344(1), 149–151. <https://doi.org/10.1016/j.carres.2008.10.004>
- Mehta, B. K., Pandit, V., & Gupta, M. (2009). New principles from seeds of *Nigella sativa*. *Natural Product Research*, 23(2), 138–148. <https://doi.org/10.1080/14786410801892078>
- Moens, A. L., Claeys, M. J., Timmermans, J. P., & Vrints, C. J. (2005). Myocardial ischemia/reperfusion-injury, a clinical view on a complex pathophysiological process. *International Journal of Cardiology*, 100(2), 179–190. <https://doi.org/10.1016/j.ijcard.2004.04.013>
- Mousavi, S. M., Sheikhi, A., Varkaneh, H. K., Zarezadeh, M., Rahmani, J., & Milajerdi, A. (2018). Effect of *Nigella sativa* supplementation on obesity indices: A systematic review and meta-analysis of randomized controlled trials. *Complementary Therapies in Medicine*, 38, 48–57. <https://doi.org/10.1016/j.ctim.2018.04.003>
- Myers, M. G., Leibel, R. L., Seeley, R. J., & Schwartz, M. W. (2010). Obesity and leptin resistance: distinguishing cause from effect. *Trends in Endocrinology & Metabolism*, 21(11), 643–651. <https://doi.org/10.1016/j.tem.2010.08.002>
- Nader, M. A., El-Agamy, D. S., & Suddek, G. M. (2010). Protective effects of propolis and thymoquinone on development of atherosclerosis in cholesterol-fed rabbits. *Arch Pharm Res*, 33(4), 637–643. <https://doi.org/10.1007/s12272-010-0420-1>
- Namazi, N., Mahdavi, R., Alizadeh, M., & Farajnia, S. (2015). Oxidative Stress Responses to *Nigella sativa* Oil Concurrent with a Low-Calorie Diet in Obese Women: A Randomized, Double-Blind Controlled Clinical Trial. *Phytotherapy Research*, 29(11), 1722–1728. <https://doi.org/10.1002/ptr.5417>
- Nikkhah-Bodaghi, M., Darabi, Z., Agah, S., & Hekmatdoost, A. (2019). The effects of *Nigella sativa* on quality of life, disease activity index, and some of inflammatory and oxidative stress factors in patients with ulcerative colitis. *Phytotherapy Research*, 33(4), 1027–1032. <https://doi.org/10.1002/ptr.6296>
- Ojha, S., Goyal, S., Kumari, S., & Arya, D. S. (2012). Pyruvate attenuates cardiac dysfunction and oxidative stress in isoproterenol-induced cardiotoxicity. *Experimental and Toxicologic Pathology*, 64(4), 393–399. <https://doi.org/10.1016/j.etp.2010.10.004>
- Oskouei, Z., Akaberi, M., & Hosseinzadeh, H. (2018). A glance at black cumin (*Nigella sativa*) and its active constituent, thymoquinone, in ischemia: a review. *Iranian Journal of Basic Medical Sciences*, 21(12), 1200–1209. <https://doi.org/10.22038/ijbms.2018.31703.7630>
- Periasamy, V. S., Athinarayanan, J., & Alshatwi, A. A. (2016). Anticancer activity of an ultrasonic nanoemulsion formulation of *Nigella sativa* L. essential oil on human breast cancer cells. *Ultrasonics Sonochemistry*, 31, 449–455. <https://doi.org/10.1016/j.ultsonch.2016.01.035>
- Pignatelli, P., Menichelli, D., Pastori, D., & Violi, F. (2018). Oxidative stress and cardiovascular disease: new insights. *Kardiologia Polska*, 76, 713–722.

- <https://doi.org/10.5603/kp.a2018.0071>
- Prabhakaran, D., Jeemon, P., & Roy, A. (2016). Cardiovascular Diseases in India. *Circulation*, 133(16), 1605–1620. <https://doi.org/10.1161/circulationaha.114.008729>
- Qidwai, W., Hamza, H. B., Qureshi, R., & Gilani, A. (2009). Effectiveness, safety, and tolerability of powdered *Nigella sativa* (kalonji) seed in capsules on serum lipid levels, blood sugar, blood pressure, and body weight in adults: results of a randomized, double-blind controlled trial. *Journal of Alternative and Complementary Medicine* (New York, N.Y.), 15(6), 639–644. <https://doi.org/10.1089/acm.2008.0367>
- Rafati, S., Niakan, M., & Mohsen Naseri. (2014). Anti-microbial effect of *Nigella sativa* seed extract against staphylococcal skin Infection. *PubMed*, 28, 42–42.
- Ragheb, A., Elbarbry, F., Prasad, K., Mohamed, A., Ahmed, M. S., & Shoker, A. (2008). Attenuation of the development of hypercholesterolemic atherosclerosis by thymoquinone. *International Journal of Angiology*, 17(04), 186–192. <https://doi.org/10.1055/s-0031-1278307>
- Rahman, K., & Lowe, G. M. (2006). Garlic and cardiovascular disease: a critical review. *The Journal of Nutrition*, 136(3 Suppl), 736S740S. <https://doi.org/10.1093/jn/136.3.736S>
- Rashidmayvan, M., Vandyousefi, S., Barati, M., Salamat, S., Ghodrat, S., Khorasanchi, M., Jahan-Mihan, A., Nattagh-Eshktivani, E., & Mohammadshahi, M. (2022). The effect of *nigella sativa* supplementation on cardiometabolic outcomes in patients with non-alcoholic fatty liver: A randomized double-blind, placebo-controlled trial. *Complementary Therapies in Clinical Practice*, 48, 101598. <https://doi.org/10.1016/j.ctcp.2022.101598>
- Rasouli, M., Okhovatian, A., & Enderami, A. (2005). Serum proteins profile as an indicator of malignancy: multivariate logistic regression and ROC analyses. *Clinical Chemistry and Laboratory Medicine (CCLM)*, 43(9). <https://doi.org/10.1515/cclm.2005.156>
- Razavi, B. M., & Hosseinzadeh, H. (2014). A review of the effects of *Nigella sativa* L. and its constituent, thymoquinone, in metabolic syndrome. *Journal of Endocrinological Investigation*, 37(11), 1031–1040. <https://doi.org/10.1007/s40618-014-0150-1>
- Razmpoosh, E., Safi, S., Nadjarzadeh, A., Fallahzadeh, H., Abdollahi, N., Mazaheri, M., Nazari, M., & Salehi-Abargouei, A. (2021). The effect of *Nigella sativa* supplementation on cardiovascular risk factors in obese and overweight women: a crossover, double-blind, placebo-controlled randomized clinical trial. *European Journal of Nutrition*, 60(4), 1863–1874. <https://doi.org/10.1007/s00394-020-02374-2>
- Reilly, M. P., Lehrke, M., Wolfe, M. L., Rohatgi, A., Lazar, M. A., & Rader, D. J. (2005). Resistin Is an Inflammatory Marker of Atherosclerosis in Humans. *Circulation*, 111(7), 932–939. <https://doi.org/10.1161/01.cir.0000155620.10387.43>
- Rona, G. (1985). Catecholamine cardiotoxicity. *Journal of Molecular and Cellular Cardiology*, 17(4), 291–306. [https://doi.org/10.1016/s0022-2828\(85\)80130-9](https://doi.org/10.1016/s0022-2828(85)80130-9)
- Sabzghabae, A., Dianatkah, M., Sarrafzadegan, N., Asgary, S., & Ghannadi, A. (2012). Clinical Evaluation of *Nigella Sativa* Seeds for the Treatment of Hyperlipidemia: a Randomized, Placebo Controlled Clinical Trial. *Medical Archives*, 66(3), 198. <https://doi.org/10.5455/medarh.2012.66.198-200>
- Sahebkar, A., Beccuti, G., Simental-Mendía, L. E., Nobili, V., & Bo, S. (2016). *Nigella sativa* (black seed) effects on plasma lipid concentrations in humans: A systematic review and meta-analysis of randomized placebo-controlled trials. *Pharmacological Research*, 106, 37–50. <https://doi.org/10.1016/j.phrs.2016.02.008>
- Sengar, N., Joshi, A., Prasad, S. K., & Hemalatha, S. (2015). Anti-inflammatory, analgesic and anti-pyretic activities of standardized root extract of *Jasminum sambac*. *Journal of Ethnopharmacology*, 160, 140–148. <https://doi.org/10.1016/j.jep.2014.11.039>
- Shabana, A., El-Menyar, A., Asim, M., Al-Azzeh, H., & Al Thani, H. (2012). Cardiovascular Benefits of Black Cumin (*Nigella sativa*). *Cardiovascular Toxicology*, 13(1), 9–21. <https://doi.org/10.1007/s12012-012-9181-z>
- Shafiq, H., Ahmad, A., Masud, T., & Kaleem, M. (2014). Cardio-protective and anti-cancer therapeutic potential of *Nigella sativa*. *PubMed*, 17(12), 967–979.
- Siavash Parvardeh, Masoumeh Sabetkasaei, Mahsa Moghimi, Alireza Masoudi, Shiva Ghafghazi, & Fatemeh Mahboobifard. (2018). Role of L-arginine/NO/cGMP/KATP channel signaling pathway in the central and peripheral antinociceptive effect of thymoquinone in rats. *PubMed*, 21(6), 625–633. <https://doi.org/10.22038/ijbms.2018.26255.6438>
- Singh Arya, D., Ojha, S. K., Nandave, M., Arora, S., Narang, R., & Dinda, A. K. (2008). Chronic Administration of *Tribulus terrestris* Linn. Extract Improves Cardiac Function and Attenuates Myocardial Infarction in Rats. *International Journal of Pharmacology*, 4(1), 1–10. <https://doi.org/10.3923/ijp.2008.1.10>
- Singh, S. (2014). Cytoprotective and regulatory functions of glutathione S-transferases in cancer cell proliferation and cell death. *Cancer Chemotherapy and Pharmacology*, 75(1), 1–15. <https://doi.org/10.1007/s00280-014-2566-x>
- Srinivasan, K. (2018). Cumin (*Cuminum cyminum*) and black cumin (*Nigella sativa*) seeds: traditional uses, chemical constituents, and nutraceutical effects. *Food Quality and Safety*, 2(1), 1–16. <https://doi.org/10.1093/fqsafe/fyx031>
- Stadtman, E. R. (2004). Role of Oxidant Species in Aging. *Current Medicinal Chemistry*, 11(9), 1105–1112. <https://doi.org/10.2174/0929867043365341>
- Subhash Padhyé, Banerjee, S., Ahmad, A., Mohammad, R. M., & Sarkar, F. H. (2008). From here to eternity - the secret of Pharaohs: Therapeutic potential of black cumin seeds and beyond. *PubMed*, 6.
- Szentandrassy, N., Szigeti, G., Szegedi, C., Sárközi, S., Magyar, J., Bányász, T., Csernoch, L., Kovács, L., Nánási, P. P., & Jóna, I. (2004). Effect of thymol on calcium handling in mammalian ventricular myocardium. *Life Sciences*, 74(7), 909–921. <https://doi.org/10.1016/j.lfs.2003.09.034>
- Tappia, P. S., Hata, T., Lena Mariam, Hozaima, Sandhu, M. S., Panagia, V., & Dhalla, N. S. (2001). Role of Oxidative Stress in Catecholamine-Induced Changes in Cardiac Sarcolemmal Ca²⁺ Transport. *Archives of Biochemistry and Biophysics*, 387(1), 85–92. <https://doi.org/10.1006/abbi.2000.2234>
- Tariq, M. (2008). *Nigella sativa* seeds: Folklore treatment in modern day medicine. *Saudi Journal of Gastroenterology*, 14(3), 105. <https://doi.org/10.4103/1319-3767.41725>
- Tavakoli-Rouzbehani, O. M., Abbasnezhad, M., Kheirouri, S., & Alizadeh, M. (2021). Effects of *Nigella sativa* oil supplementation on selected metabolic parameters and anthropometric indices in patients with coronary artery disease: A randomized, double-blind, placebo-controlled clinical trial. *Phytotherapy Research*, 35(7), 3988–3999. <https://doi.org/10.1002/ptr.7115>
- Tavakoli-Rouzbehani, O. M., Abbasnezhad, M., Kheirouri, S., & Alizadeh, M. (2022). Efficacy of *nigella sativa* oil on endothelial function and atherogenic indices in patients with coronary artery diseases: A randomized, double-blind, placebo-control clinical trial. *Phytotherapy Research*, 36(12). <https://doi.org/10.1002/ptr.7568>
- Toktam Ziaee, N Moharreri, & Hosseinzadeh, H. (2012). Review Of Pharmacological And Toxicological Effects Of *Nigella Sativa* And Its Active Constituents. *Journal of Medicinal Plants*, 11(42), 16–42.
- Tullio, F., Angotti, C., Perrelli, M.-G., Penna, C., & Pagliaro, P. (2013). Redox balance and cardioprotection. *Basic Research in Cardiology*, 108(6). <https://doi.org/10.1007/s00395-013-0392-7>

- Uz, E., Bayrak, O., Uz, E., Kaya, A., Bayrak, R., Uz, B., Turgut, F. H., Bavbek, N., Kanbay, M., & Akcay, A. (2008). Nigella sativa Oil for Prevention of Chronic Cyclosporine Nephrotoxicity: An Experimental Model. *American Journal of Nephrology*, 28(3), 517–522.
<https://doi.org/10.1159/000114004>
- Vida Nesar Hoseini, & Mehdi Rasouli. (2009). Microalbuminuria correlates with the prevalence and severity of coronary artery disease in non-diabetic patients. *PubMed*, 16(2), 142–145.
- Violi, F., Loffredo, L., Carnevale, R., Pignatelli, P., & Pastori, D. (2017). Atherothrombosis and Oxidative Stress: Mechanisms and Management in Elderly. *Antioxidants & Redox Signaling*, 27(14), 1083–1124.
<https://doi.org/10.1089/ars.2016.6963>
- Zhang, J.-L., Qin, Y., Zheng, X., Qiu, J., & Zou, D. (2003). Serum resistin level in essential hypertension patients with different glucose tolerance. *Diabetic Medicine*, 20(10), 828–831. <https://doi.org/10.1046/j.1464-5491.2003.01057.x>
- Zhang, T., Yang, S., & Du, J. (2014). Protective Effects of Berberine on Isoproterenol-Induced Acute Myocardial Ischemia in Rats through Regulating HMGB1-TLR4 Axis. *Evidence-Based Complementary and Alternative Medicine*, 2014, 1–8.
<https://doi.org/10.1155/2014/849783>